Clinical Research Directory
Browse clinical research sites, groups, and studies.
COVID-19 International Drug Pregnancy Registry
Sponsor: Pregistry
Summary
The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.
Official title: COVID-19 International Drug Pregnancy Registry (COVID-PR)
Key Details
Gender
FEMALE
Age Range
18 Years - 50 Years
Study Type
OBSERVATIONAL
Enrollment
2000
Start Date
2021-12-01
Completion Date
2027-09-30
Last Updated
2025-09-26
Healthy Volunteers
No
Conditions
Interventions
Antiviral Agents
Antiviral medications indicated for the treatment of mild to severe COVID-19
Monoclonal antibody
Monoclonal antibodies indicated for the treatment of mild to severe COVID-19
Locations (1)
Pregistry
Los Angeles, California, United States